The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia

For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a maj...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yu, Pan, Liangqin, Hong, Ming, Liu, Weixing, Qiao, Chun, Li, Jianyong, Qian, Sixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Department of Journal of Biomedical Research 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138586/
https://www.ncbi.nlm.nih.gov/pubmed/27924071
http://dx.doi.org/10.7555/JBR.30.20130172
_version_ 1782472090491813888
author Zhu, Yu
Pan, Liangqin
Hong, Ming
Liu, Weixing
Qiao, Chun
Li, Jianyong
Qian, Sixuan
author_facet Zhu, Yu
Pan, Liangqin
Hong, Ming
Liu, Weixing
Qiao, Chun
Li, Jianyong
Qian, Sixuan
author_sort Zhu, Yu
collection PubMed
description For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a major molecular response with the combination of imatinib and dasatinib with no significant extramedullary toxicity. Our observations suggest that combination of TKIs may provide an additive/synergistic antileukemic effect.
format Online
Article
Text
id pubmed-5138586
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial Department of Journal of Biomedical Research
record_format MEDLINE/PubMed
spelling pubmed-51385862016-12-16 The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia Zhu, Yu Pan, Liangqin Hong, Ming Liu, Weixing Qiao, Chun Li, Jianyong Qian, Sixuan J Biomed Res Case Report For patients with chronic myeloid leukemia (CML) failing imatinib therapy, second-generation tyrosine kinase inhibitors (TKIs) are recommended. Here, we describe two patients with advanced CML who failed imatinib therapy and did not tolerate the recommended dose of dasatinib, but then achieved a major molecular response with the combination of imatinib and dasatinib with no significant extramedullary toxicity. Our observations suggest that combination of TKIs may provide an additive/synergistic antileukemic effect. Editorial Department of Journal of Biomedical Research 2016-11 2014-09-07 /pmc/articles/PMC5138586/ /pubmed/27924071 http://dx.doi.org/10.7555/JBR.30.20130172 Text en © 2016 by the Journal of Biomedical Research. All rights reserved.
spellingShingle Case Report
Zhu, Yu
Pan, Liangqin
Hong, Ming
Liu, Weixing
Qiao, Chun
Li, Jianyong
Qian, Sixuan
The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title_full The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title_fullStr The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title_full_unstemmed The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title_short The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
title_sort combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138586/
https://www.ncbi.nlm.nih.gov/pubmed/27924071
http://dx.doi.org/10.7555/JBR.30.20130172
work_keys_str_mv AT zhuyu thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT panliangqin thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT hongming thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT liuweixing thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT qiaochun thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT lijianyong thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT qiansixuan thecombinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT zhuyu combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT panliangqin combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT hongming combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT liuweixing combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT qiaochun combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT lijianyong combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia
AT qiansixuan combinationtherapyofimatinibanddasatinibachieveslongtermmolecularresponseintwoimatinibresistantanddasatinibintolerantpatientswithadvancedchronicmyeloidleukemia

Ejemplares similares